The FDA approved rusfertide (Mimrylo) from Takeda and Protagonist Therapeutics for polycythemia vera, a rare blood disorder in which excess red blood cell production increases risk for complications. The clearance brings a hepcidin mimetic approach into clinical use for PV. The approval builds on phase 3 efficacy results cited by Takeda’s program communications, extending treatment options for PV patients beyond standard cytoreductive and phlebotomy-based strategies. As PV management continues to demand better control with acceptable tolerability, the regulatory action positions rusfertide as a mechanism-based option tied to iron regulation through hepcidin pathway engagement.